MedTrace Logo

A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function

NCT06929156 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-02-11

No results posted yet for this study

Summary

The purpose of this study is to assess how fast BGM0504 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)
  • Overweight or Obese

Interventions

DRUG

BGM0504

Receive a single dose of BGM0504 injection

DRUG

BGM0504

Receive a single dose of BGM0504 injection

DRUG

BGM0504

Receive a single dose of BGM0504 injection

DRUG

BGM0504

Receive a single dose of BGM0504 injection

Sponsors & Collaborators

  • BrightGene Bio-Medical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-06
Primary Completion
2025-12-25
Completion
2025-12-25
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06929156 on ClinicalTrials.gov